Background Image
Previous Page  23 / 188 Next Page
Information
Show Menu
Previous Page 23 / 188 Next Page
Page Background

NCCN Guidelines Index

Breast Cancer Table of Contents

Discussion

Version2.2015, 03/11/2015© National Comprehensive Cancer Network, Inc. 2015,All rights reserved.The NCCN Guidelines

®

and this illustration may not be reproduced in any form without the express written permission of NCCN

®

.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

BINV-11

NCCN Guidelines Version 2.2015

Invasive Breast Cancer

Preoperative Systemic Therapy Breast and Axillary Evaluation

Core biopsy with placement

of image-detectable

marker(s), if not previously

performed, must be done to

demarcate the tumor bed for

post-chemotherapy surgical

management

Clinically negative axillary

lymph node(s) should

have axillary imaging;

suspicious nodes should

be sampled by FNA or

core biopsy prior to

neoadjuvant therapy

ee

Clinically positive axillary

lymph node(s) should

be sampled by FNA or

core biopsy prior to

neoadjuvant therapy

ee

See Locoregional Treatment of Clinical Stage I, IlA, or IlB Disease

or T3, N1, M0 (BINV-3)

See Preoperative

Systemic Therapy -

Primary Treatment

(BINV-12)

Preoperative

systemic

therapy

Surgical resection

ee

Marking of sampled axillary nodes with a tattoo or clip should be considered to permit verification that the biopsy-positive lymph node has been removed at the time of

definitive surgery.

ff

Among patients shown to be node-positive prior to neoadjuvant systemic therapy, SLNB has a >10% false-negative rate when performed after neoadjuvant systemic

therapy. This rate can be improved by marking biopsied lymph nodes to document their removal, using dual tracer, and by removing more than 2 sentinel nodes.

If lymph node FNA or core

biopsy negative, SLNB can

be performed before or

after neoadjuvant systemic

therapy

If lymph node FNA or core

biopsy positive, axilla

may be restaged after

neoadjuvant systemic

therapy; ALND should

be performed if axilla is

clinically positive; SLNB or

ALND can be performed if

axilla is clinically negative

ff